Definium Therapeutics (NASDAQ:DFTX) Shares Gap Up - What's Next?

Key Points

• Definium Therapeutics shares surged after the company reported positive topline results from the Phase 3 Voyage study of DT120 ODT for generalized anxiety disorder, marking its second positive Phase 3 trial and supporting potential future regulatory filing.
• Analysts remain broadly bullish, with a consensus “Buy” rating and an average price target of $55; several firms recently raised targets to between $57 and $75.
• Despite clinical progress, Definium remains loss-making: it missed its latest quarterly EPS estimate, faces lower forward earnings forecasts, and insiders have sold roughly 48,096 shares over the past 90 days.

Shares of Definium Therapeutics, Inc. (NASDAQ:DFTX - Get Free Report) gapped up before the market opened on Wednesday . The stock had previously closed at $40.91, but opened at $47.51. Definium Therapeutics shares last traded at $42.85, with a volume of 2,741,718 shares traded.

More Definium Therapeutics News

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: Definium announced positive topline results from the Phase 3 Voyage study, saying DT120 ODT reduced anxiety symptoms in patients with generalized anxiety disorder. The study is the second of two positive Phase 3 trials for the therapy, providing important validation for the program and supporting investor expectations for a future filing. Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study
• Positive Sentiment: Coverage characterized the result as another successful late-stage study for Definium’s LSD-based anxiety drug, triggering a strong rally in the biotech stock. Investors are likely focusing on the potential size of the anxiety-treatment market and the reduced clinical risk following two positive Phase 3 outcomes. This LSD-Based Drug Just Scored Again. Definium Stock Soars.
• Neutral Sentiment: Trading in DFTX was temporarily halted for pending news before the clinical announcement. Such halts can increase short-term volatility but do not independently alter the company’s fundamentals.
• Neutral Sentiment: Reports published before the trial announcement said investors were awaiting the anxiety data and that the stock faced the possibility of its worst session in months. The subsequent positive results superseded that immediate concern. DFTX stock on track for worst day in 9 months as investors brace for anxiety trial data
• Negative Sentiment: HC Wainwright cut its EPS forecasts across 2026-30, including reducing its FY2026 estimate to a loss of $3.05 per share from $2.10 and its FY2027 estimate to a loss of $1.71 from $1.22. The revisions underscore that Definium remains loss-making and that near-term spending and commercialization timing remain risks, despite the clinical progress.

Analyst Ratings Changes

DFTX has been the topic of a number of research reports. JonesTrading boosted their target price on shares of Definium Therapeutics from $61.00 to $74.00 and gave the company a "buy" rating in a research report on Wednesday, June 24th. Citigroup reiterated a "buy" rating on shares of Definium Therapeutics in a report on Monday, June 22nd. Wells Fargo & Company assumed coverage on Definium Therapeutics in a research report on Monday, July 27th. They issued an "overweight" rating and a $68.00 target price for the company. Robert W. Baird lifted their price objective on shares of Definium Therapeutics from $37.00 to $57.00 and gave the company an "outperform" rating in a report on Tuesday, June 23rd. Finally, Piper Sandler reissued an "overweight" rating and issued a $75.00 price objective (up from $73.00) on shares of Definium Therapeutics in a research note on Friday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock has an average rating of "Buy" and an average target price of $55.00.

Definium Therapeutics Stock Performance

The company has a debt-to-equity ratio of 0.04, a current ratio of 6.95 and a quick ratio of 6.95. The company's fifty day moving average price is $38.68 and its 200 day moving average price is $26.34. The company has a market cap of $4.39 billion, a PE ratio of -12.84 and a beta of 2.23.

Definium Therapeutics (NASDAQ:DFTX - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($1.44) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.89). On average, equities research analysts predict that Definium Therapeutics, Inc. will post -2.65 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Robert Barrow sold 29,208 shares of the firm's stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $1,315,236.24. Following the completion of the sale, the chief executive officer owned 1,098,246 shares in the company, valued at $49,454,017.38. This trade represents a 2.59% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Matthew T. Wiley sold 2,867 shares of the stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $129,101.01. Following the transaction, the insider directly owned 174,633 shares of the company's stock, valued at approximately $7,863,723.99. This trade represents a 1.62% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 48,096 shares of company stock valued at $2,165,763. 2.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Definium Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Cerity Partners LLC grew its stake in Definium Therapeutics by 2.4% in the 2nd quarter. Cerity Partners LLC now owns 49,650 shares of the company's stock valued at $322,000 after buying an additional 1,165 shares in the last quarter. Creative Planning grew its position in shares of Definium Therapeutics by 2.6% in the second quarter. Creative Planning now owns 66,097 shares of the company's stock valued at $429,000 after purchasing an additional 1,655 shares in the last quarter. Russell Investments Group Ltd. grew its position in shares of Definium Therapeutics by 110.4% in the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company's stock valued at $25,000 after purchasing an additional 2,003 shares in the last quarter. Mercer Global Advisors Inc. ADV grew its position in shares of Definium Therapeutics by 10.5% in the third quarter. Mercer Global Advisors Inc. ADV now owns 21,931 shares of the company's stock valued at $259,000 after purchasing an additional 2,079 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its stake in shares of Definium Therapeutics by 5.1% during the 2nd quarter. JPMorgan Chase & Co. now owns 48,487 shares of the company's stock valued at $315,000 after purchasing an additional 2,342 shares during the period. 27.91% of the stock is currently owned by institutional investors.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source